Sciformix’s RightOutcomes Analytics Solution leverages domain expertise and a leading life sciences technology platform to enable better insights for real world applications
19 May 2018, Boston, MA — Sciformix Corporation, a leading scientific knowledge-based organization, today announced the launch of RightOutcomes, a Real World Evidence (RWE) Analytics Solution that will allow life science companies to leverage the power of real world data to its fullest.
In today’s environment, HEOR (Health Economics and Outcomes Research) and RWE professionals struggle with the large volumes of Real World Data (RWD), especially when identifying the required datasets, data handling and curation, querying different cohorts and patient subgroups, and separating signal from noise to make the data analysis-ready and generate insights. The combination of large volume and intrinsic complexity of RWD requires a hybrid approach that combines both RWE domain expertise and innovative analytical tools.
RightOutcomes leverages the company’s RWE and analytical expertise, and a customization of Saama Technologies’ cloud based life science analytics platform for RWE applications. RightOutcomes is an integrated solution that employs the right knowledge, tools and methodologies to pool, extract and analyze data in a single application to help organizations gain insight into predefined questions and hypotheses; identify optimized cohorts and settings; and refine hypotheses via more effective analyses of real world datasets.
The solution allows for comparative effectiveness, adherence and long-term safety profiling, patient sub-group benefit analysis and unmet need identification. The RightOutcomes solution integrates disparate data sources and a leading analytics infrastructure with the RWE domain expertise and support for better insight throughout the product life cycle. Some examples of the advanced analyses that will provide added value and insights to organizations include the ability to:
- Analyze the relation between baseline characteristics and outcomes of interest, while comparing two or more patient cohorts to identify differential effectiveness.
- Study and analyze various patient treatments and progression through the patient pathway analytics tracker.
- Identify patients at risk for outcomes of interest (e.g. stroke or heart failure) and analyze endpoints, Patient Reported Outcomes (PRO’s), economic outcomes and cost drivers for patient groups.
Sciformix President and CEO, Manish Soman, commented: “Sciformix is excited to launch our RightOutcomes solution which will enhance the ability to gain an understanding of disease epidemiology, patient journey, and real-world use and effectiveness of treatment options. This is a comprehensive solution to address the common challenge of integrating disparate data sources and analytics infrastructure and further evidence of Sciformix’s continued investment in the area of RWE.”
Sciformix will be discussing and presenting this powerful solution at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018, May 19-23rd in Baltimore, MD, USA at Booth #809. To schedule a meeting at ISPOR email firstname.lastname@example.org.
Sciformix, headquartered in the United States with operations in Europe, India, and the Philippines, partners with life science organizations to provide a full range of services, from study design to post-marketing surveillance. Areas of specialization include safety and risk management, clinical development, real world evidence and market research, scientific writing, regulatory affairs, and technology services.
For further press information please contact: Scott Girling-Heathcote, The Scott Partnership: + 44 1477 539539 mail to email@example.com or Susan Najjar, Director of Marketing, Sciformix Corporation: + 1 617-264-0339 mail to firstname.lastname@example.org.
Sciformix Corporation is a leading scientific knowledge-based organization that provides process, technology and consulting services to the life sciences industry. We employ best-in-class strategies, technologies and expertise that accelerates business, drives higher levels of performance and fosters innovation. What differentiates Sciformix is our ability to integrate scientific and technology expertise with quality driven processes to provide value to our clients throughout the entire drug development cycle. Our areas of specialization include Safety & Risk Management, Clinical Research & Post-Approval Support Services, Regulatory Affairs & Regulatory Operations, Real World Evidence & Market Access, and Technology Services. Corporate headquarters is located in Westborough, MA with operations in NA, Europe, India and the Philippines.
We create value for our clients through our singular focus on the life sciences industry, strong pharmaceutical domain competency, exceptional subject matter expertise, uncompromising focus on quality, process rigor, predictable results, and ability to scale. Our portfolio of services spans the full spectrum of product lifecycle from pre-clinical and clinical to post marketing activities to help our customers solve complex analytical challenges, improve the quality of patient healthcare and increase client productivity.
Sciformix is dedicated to providing our clients outstanding services and solutions, fueled by an unrivalled commitment to quality. We share the same level of involvement, dedication and passion as our clients and become an integral part of their team. Our distinct combination of scientific expertise, process rigor and technology innovation delivers consistent, reliable and insightful results. Our ability to scale and grow to meet your evolving needs means we are flexible and dedicated to your success in delivering safe products with more efficiency and greater speed. We help you make the right decisions at the right time by providing Trusted Services Built